Randomized Phase II Study of Everolimus Alone (E) versus Everolimus plus Bevacizumab (E+B) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors, CALGB 80701 (Alliance)
- Citation:
- J Clin Oncol vol 33 (suppl) abstr 4005
- Meeting Instance:
- ASCO 2015
- Year:
- 2015
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3473
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, CA31946, CA025224
- Corr. Author:
- Matthew Kulke
- Authors:
- Matthew H. Kulke Donna Niedzwiecki Nathan R. Foster Bryant Fruth Pamela L. Kunz Hagen Kennecke Edward M. Wolin Alan P. Venook
- Networks:
- CA824, LAPS-CT018, LAPS-MA036, LAPS-MN026, NY021, OR013
- Study
- CALGB-80701
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: